Eylea and the newer Eylea HD are both injectable medications used to treat certain serious eye conditions caused by abnormal blood vessel growth or leakage. The main difference between the two ...
People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...
Eylea (aflibercept) injections can cause both mild and serious side effects, though serious side effects are rare according to clinical trials. Mild side effects include eye floaters, redness, and ...
The cost of Eylea, an injectable medication for certain eye conditions, may vary based on your insurance coverage, treatment plan, and location of injections. Prior authorization may be required ...
Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Eylea for the treatment of retinopathy of prematurity in preterm infants, according to a press ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
The US FDA has approved Regeneron Pharmaceuticals' (NASDAQ:REGN) high-dose ("HD") version of its blockbuster therapy Eylea (aflibercept). The new formulation allows patients to receive treatment less ...
EYLEA HD has shown impressive durable visual improvements and rapid and resilient fluid control with a safety profile comparable to EYLEA Extended dosing intervals with EYLEA HD have the potential to ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Four years after scoring an approval to treat diabetic retinopathy—a disease that strikes more than a third of those with diabetes and is the primary cause of blindness in the U.S.—Regeneron’s Eylea ...
In a little more than three months, Genentech has gained two FDA approvals to treat wet-age related macular degeneration (AMD). The second came on Friday with the FDA’s blessing of Vabysmo (faricimab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback